Company Filing History:
2 out of 1,745 
2 out of 5,094 
2 out of 54 
Years Active: 2016-2017
Title: Mathilde Bobinet: Innovator in Melanoma Research
Introduction
Mathilde Bobinet is a prominent inventor based in Nantes, France. She has made significant contributions to the field of melanoma research, holding 2 patents related to melanoma antigen peptides. Her work focuses on developing innovative solutions for the prevention and treatment of melanoma in patients.
Latest Patents
Mathilde Bobinet's latest patents include a melanoma antigen peptide that comprises specific amino acid sequences. The first patent relates to a peptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5, or a function-conservative variant thereof. This invention is aimed at preventing or treating melanoma in patients. The second patent also pertains to a melanoma antigen peptide, which includes sequences from SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15, or a function-conservative variant thereof, with similar applications in melanoma treatment.
Career Highlights
Throughout her career, Mathilde Bobinet has worked with esteemed organizations such as the Institut National de la Santé et de la Recherche Médicale and the Centre National de la Recherche Scientifique. Her experience in these institutions has allowed her to advance her research and contribute to significant medical innovations.
Collaborations
Mathilde has collaborated with notable colleagues, including Nathalie Labarriere and Anne Rogel. These partnerships have enriched her research and expanded the impact of her work in the field of melanoma.
Conclusion
Mathilde Bobinet is a dedicated inventor whose work in melanoma research is paving the way for new treatment options. Her innovative patents and collaborations highlight her commitment to advancing medical science and improving patient outcomes.